End to end CDMO services for the importation, encapsulation and distribution of T3S and Placebo for the LIONNS-D2 Trial
What the buyer wrote
Award notice for the above CDMO services tender. Previous description as follows - The School of Medicine successfully applied for a UKRI grant to investigate in a randomised controlled trial (RCT), a new IMP (investigational medicinal product) called Triiodothyronine sulphate (T3S) in hypothyroid subjects with a gene difference in a thyroid related enzyme called deiodinase 2 (D2). We are looking for a CDMO to (i) Import and QP sign off T3S and matched placebo tablets obtained from Ardena, Pamplona, Spain who will manufacture these to GMP standards; (ii) over encapsulate commercially secured L-thyroxine (LT4 ) and matched placebo capsules; (iii) store T3S and matched placebo obtained from A…
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- End to end CDMO services for the importation, encapsulation and distribution of T3S and Placebo for the LIONNS-D2 Trial
- How they are buying
- Advertised, then negotiatedThe buyer talked terms with bidders rather than taking fixed offers.
- Type
- services
- Work starts
- 4 Oct 2026
- Work ends
- 1 Oct 2027
- Where
- in Wales
- Kind of work
- Research, evaluation and insight, Pharmacy and medicines
Who the buyer named
The buyer published a contact address on this notice.
